Expertise in
5
conditions

Dr. Randeep S. Sangha

Oncology
4501 X St, Suite 3019, 
Sacramento, CA 
Expertise in
5
conditions
4501 X St, Suite 3019, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Randeep Sangha is an Oncologist in Sacramento, California. Dr. Sangha is highly rated in 5 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Non-Hodgkin Lymphoma, and Febrile Neutropenia.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4501 X St, Suite 3019, Sacramento, CA 95817

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies
Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: April 17, 2025
Intervention Type: Drug
Study Drug: PCLX-001
Study Phase: Phase 1
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 6 Less Clinical Trials

43 Total Publications

Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 08, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Janai R. Carr-Ascher
Oncology | Hematology
Expertise in
22
conditions
Dr. Janai R. Carr-Ascher
Oncology | Hematology

Regents Of The Univ Of Ca

4501 X St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Janai Carr-Ascher is an Oncologist and a Hematologist in Sacramento, California. Dr. Carr-Ascher is highly rated in 22 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Bone Tumor, Undifferentiated Pleomorphic Sarcoma, and Mesenchymoma.

Expertise in
19
conditions
Dr. Jonathan W. Riess
Hematology Oncology | Hematology | Oncology
Expertise in
19
conditions
Dr. Jonathan W. Riess
Hematology Oncology | Hematology | Oncology

Regents Of The Univ Of Ca

2315 Stockton Blvd, 
Sacramento, CA 
 (0.2 miles away)
916-734-2011
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Riess is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Riess is highly rated in 19 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Bone Marrow Aspiration, and Gastrostomy.

Elias N. Kiwan
Expertise in
40
conditions
Dr. Elias N. Kiwan
Oncology
Expertise in
40
conditions
Dr. Elias N. Kiwan
Oncology

Buhler Specialty Pavilion

2800 L Street, Suite 260, 
Sacramento, CA 
 (1.5 miles away)
916-733-4400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elias Kiwan is an Oncologist in Sacramento, California. Dr. Kiwan is highly rated in 40 conditions, according to our data. His top areas of expertise are Thrombocytopenia, Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Bone Marrow Aspiration. Dr. Kiwan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sangha's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile